Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 1/20 | 0.51 |
| ▸ | PDE2A | O00408 | 3/20 | 0.49 |
| ▸ | MRGPRX4 | Q96LA9 | 4/20 | 0.46 |
| ▸ | HTR2A | P28223 | 3/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.41 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | GABRB3 | P28472 | 3/20 | 0.40 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.40 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.40 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24987667 | 0.86 | EPHX2 (0.42) | DAOPDE2AMRGPRX4EPHX2NR1H4 | |
| SCHEMBL12603777 | 0.85 | KIF11 (0.50) | DAOEPHX2NR1H4 | |
| SCHEMBL10050765 | 0.84 | SLC6A4 (0.46) | PDE2AMRGPRX4HTR2ASLC6A4KCNH2 | |
| SCHEMBL3211500 | 0.82 | DAO (0.49) | DAOPDE2AMRGPRX4HTR2ASLC6A4 | |
| SCHEMBL10235441 | 0.82 | CYP2C19 (0.47) | EPHX2NR1H4 | |
| SCHEMBL15133743 | 0.81 | ESR1 (0.44) | DAOPDE2AHTR2ASLC6A4KCNH2 | |
| SCHEMBL16997378 | 0.81 | PDE2A (0.46) | DAOPDE2AMRGPRX4HTR2ASLC6A4 | |
| SCHEMBL20181909 | 0.80 | DAO (0.43) | DAOPDE2AMRGPRX4HTR2ASLC6A4 | |
| SCHEMBL3765975 | 0.80 | DAO (0.48) | DAOPDE2AMRGPRX4HTR2ASLC6A4 | |
| SCHEMBL963581 | 0.80 | DAO (0.48) | DAOPDE2AMRGPRX4HTR2ASLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023220223-A1 | INHIBITORS OF HUMAN RESPIRATORY SYNCYTIAL VIRUS AND METAPNEUMOVIRUS | MERCK SHARP & DOHME LLC (US) | 2023-11-16 | — | — | WO | disclosed |
| US-11566015-B2 | Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | Crinetics Pharmaceuticals, Inc. (US) | 2023-01-31 | — | — | US | disclosed |
| EP-3702355-B1 | SUBSTITUTED PYRAZOLE COMPOUNDS CONTAINING PYRIMIDINE, THE PREPARATION AND APPLICATION THEREOF | SHENYANG SINOCHEM AGROCHEMICALS R & D CO LTD (CN) | 2022-01-12 | — | — | EP | disclosed |
| US-20210238164-A1 | MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. | 2021-08-05 | — | — | US | disclosed |
| WO-2021102314-A1 | TRPV4 RECEPTOR LIGANDS | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2021-05-27 | — | — | WO | disclosed |
| WO-2021083185-A1 | PYRIMIDINE-CONTAINING PIPERIDINAMINE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | 沈阳中化农药化工研发有限公司 | 2021-05-06 | — | — | WO | disclosed |
| EP-2913325-B1 | SUBSTITUTED PYRIMIDINE COMPOUND AND USES THEREOF | SHENYANG SINOCHEM AGROCHEMICALS R & D CO LTD (CN) | 2021-04-21 | — | — | EP | disclosed |
| US-10981894-B2 | Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | Crinetics Pharmaceuticals, Inc. (US) | 2021-04-20 | — | — | US | disclosed |
| EP-3760617-A1 | SUBSTITUTED PYRIMIDINE COMPOUND AND USES THEREOF | Shenyang Sinochem Agrochemicals R&D Co., Ltd. (CN) | 2021-01-06 | — | — | EP | disclosed |
| US-10821100-B2 | Triazolone compounds as mPGES-1 inhibitors | Ichnos Sciences SA (CH) | 2020-11-03 | — | — | US | disclosed |
| US-7879862-B2 | Central nervous system disorders; psychological disorders; anxiolytic agents; irritable bowel syndrome; antidepressants | SMITHKLINE BEECHAM (CORK) LIMITED (IE) | 2011-02-01 | — | — | US | disclosed |
| WO-2010098948-A1 | GLUCAGON RECEPTOR ANTAGONIST COMPOUNDS, COMPOSITIONS CONTAININ SUCH COMPOUNDS AND METHODS OF USE | MERCK SHARP & DOHME CORP. (US) | 2010-09-02 | — | — | WO | disclosed |
| US-20100160411-A1 | BENZOXATHIINE AND BENZOXATHIOLE DERIVATIVES AND USES THEREOF | WYETH (US) | 2010-06-24 | — | — | US | disclosed |
| US-20100035871-A1 | BENZOXAZINE DERIVATIVES AND USES THEREOF | WYETH | 2010-02-11 | — | — | US | disclosed |
| US-7557113-B2 | Substituted pyrrolo[3,2-d]pyrimidine derivatives | TEIJIN PHARMA LIMITED (JP) | 2009-07-07 | — | — | US | disclosed |
| US-7557113-B2 | Substituted pyrrolo[3,2-d]pyrimidine derivatives | TEIJIN PHARMA LIMITED (JP) | 2009-07-07 | — | — | US | disclosed |
| US-20080194545-A1 | ANTIMICROBIAL COMPOSITIONS AND METHODS OF USE | TRIUS THERAPEUTICS (US) | 2008-08-14 | — | — | US | disclosed |
| US-20080194589-A1 | Pyrazolo[1,5-Alpha]Pyrimidinyl Derivatives Useful as Corticotropin-Releasing Factor (Crf) Receptor Antagonists | NEUROCRINE BIOSCIENCES, INC. (US) | 2008-08-14 | — | — | US | disclosed |
| US-20080182891-A1 | CHROMANE AND CHROMENE DERIVATIVES AND USES THEREOF | WYETH (US) | 2008-07-31 | — | — | US | disclosed |
| US-7365095-B2 | Chromane and chromene derivatives and uses thereof | WYETH (US) | 2008-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160411-A1 | BENZOXATHIINE AND BENZOXATHIOLE DERIVATIVES AND USES THEREOF | HTR2C, HTR3B, HTR1A | DAO 1010/4885PDE2A 528/4885MRGPRX4 78/4885 |
| US-20080182891-A1 | CHROMANE AND CHROMENE DERIVATIVES AND USES THEREOF | HTR1A, HTR2C, CHRM1 | DAO 2546/4885PDE2A 704/4885MRGPRX4 298/4885 |
| US-11566015-B2 | Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | MC3R, MC1R, MC2R | DAO 2280/4885PDE2A 1206/4885MRGPRX4 76/4885 |
| US-20080194545-A1 | ANTIMICROBIAL COMPOSITIONS AND METHODS OF USE | ABCB11, FPR1, C5 | DAO 996/4885PDE2A 1501/4885MRGPRX4 1183/4885 |
| US-20210238164-A1 | MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF | MC3R, MC1R, MC2R | DAO 2280/4885PDE2A 1206/4885MRGPRX4 76/4885 |
| US-20100035871-A1 | BENZOXAZINE DERIVATIVES AND USES THEREOF | HTR2C, HTR5A, NPY1R | DAO 1143/4885PDE2A 654/4885MRGPRX4 107/4885 |
| US-10821100-B2 | Triazolone compounds as mPGES-1 inhibitors | PTGES, PTGS1, PTGIS | DAO 1800/4885PDE2A 184/4885MRGPRX4 101/4885 |
| US-20080194589-A1 | Pyrazolo[1,5-Alpha]Pyrimidinyl Derivatives Useful as Corticotropin-Releasing Factor (Crf) Receptor Antagonists | CRHR1, CRH, CRHR2 | DAO 620/4885PDE2A 739/4885MRGPRX4 130/4885 |
| US-10981894-B2 | Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | MC3R, MC1R, MC2R | DAO 2280/4885PDE2A 1206/4885MRGPRX4 76/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.